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OBJECTIVE—The results of the Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interventions and Com-
plications cohort study revealed a strong association between
dyslipidemia and the development of diabetic retinopathy. How-
ever, there are no experimental data on retinal fatty acid metab-
olism in diabetes. This study determined retinal-speciﬁc fatty
acid metabolism in control and diabetic animals.
RESEARCH DESIGN AND METHODS—Tissue gene and pro-
tein expression proﬁles were determined by quantitative RT-PCR
and Western blot in control and streptozotocin-induced diabetic
rats at 3–6 weeks of diabetes. Fatty acid proﬁles were assessed
by reverse-phase high-performance liquid chromatography, and
phospholipid analysis was performed by nano-electrospray ion-
ization tandem mass spectrometry.
RESULTS—We found a dramatic difference between retinal and
liver elongase and desaturase proﬁles with high elongase and low
desaturase gene expression in the retina compared with liver.
Elovl4, an elongase expressed in the retina but not in the liver,
showed the greatest expression level among retinal elongases,
followed by Elovl2, Elovl1, and Elovl6. Importantly, early-stage
diabetes induced a marked decrease in retinal expression levels
of Elovl4, Elovl2, and Elovl6. Diabetes-induced downregulation
of retinal elongases translated into a signiﬁcant decrease in total
retinal docosahexaenoic acid, as well as decreased incorporation
of very-long-chain polyunsaturated fatty acids (PUFAs), particu-
larly 32:6n3, into retinal phosphatidylcholine. This decrease in n3
PUFAs was coupled with inﬂammatory status in diabetic retina,
reﬂected by an increase in gene expression of proinﬂammatory
markers interleukin-6, vascular endothelial growth factor, and
intercellular adhesion molecule-1.
CONCLUSIONS—This is the ﬁrst comprehensive study demon-
strating diabetes-induced changes in retinal fatty acid metabo-
lism. Normalization of retinal fatty acid levels by dietary means
or/and modulating expression of elongases could represent a po-
tential therapeutic target for diabetes-induced retinal inﬂam-
mation. Diabetes 59:219–227, 2010
E
arly diabetic retinopathy has been suggested to
be a low-grade chronic inﬂammatory disease
(1–3) with a number of inﬂammatory markers,
such as vascular endothelial growth factor
(VEGF) (4,5), intercellular adhesion molecule (ICAM)-1
(6,7), tumor necrosis factor (TNF)- (8), and interleukin
(IL)-6 (9), shown to be upregulated in diabetic retina. The
individual molecular steps leading to inﬂammation in the
retina are not well resolved but likely involve hyperglyce-
mia and dyslipidemia associated with diabetes.
Dyslipidemia is a major metabolic disorder of diabe-
tes, and the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Compli-
cations cohort study revealed that dyslipidemia was
signiﬁcantly associated with the development of dia-
betic retinopathy (10). Diabetic dyslipidemia is the
result of an imbalance in the complex regulation of lipid
uptake, metabolism, release by adipocytes, and clear-
ance from circulation (11,12). Fatty acid metabolism
perturbation in diabetes is an important part of diabetic
dyslipidemia (13).
To understand the effects of diabetes on plasma and
tissue fatty acid composition, two metabolic routes have
to be considered: de novo lipogenesis and the poly-
unsaturated fatty acid (PUFA) remodeling Sprecher
pathway (14). Saturated fatty acids (SRAs), mono-
unsaturated fatty acids (MUFAs), and PUFAs are syn-
thesized from dietary precursors (glucose, palmitic16:0,
oleic18:1n9, linoleic18:2n6, -linolenic18:3n3, eicosapentaenoic
acid [EPA20:5n3], and docosahexaenoic acid [DHA22:6n3])
through a series of desaturation (5-desaturase [5D],
6-desaturase [6D], or 9-desaturase [9D]) and elonga-
tion (Elovl1–7) reactions. In the recent work by Agbaga et
al. (15), the Sprecher pathway was expanded to include
very-long-chain PUFAs (VLCPUFAs), up to 38 carbon fatty
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precursors is performed by Elovl4 (Fig. 1). Elovl4 has very
limited tissue speciﬁcity. It is highly expressed in the
retina (16–18), thymus, and skin (17), as well as at lesser
levels in the brain (17,18) and testis (18). Elovl4 is not
expressed in the liver (17,18). In human retina, Elovl4 was
shown to be primarily expressed in the inner segment of
photoreceptors extending to photoreceptor cell bodies in
the outer nuclear layer (19). Moderate labeling was also
observed in the ganglion cells (19). Elovl4 has received
much attention recently, as an autosomal-dominant Star-
gardt-like macular dystrophy was linked to several domi-
nant-negative mutations in Elovl4 (19–21). The role of
VLCPUFAs produced by Elovl4 is not known, but because
of their localization in retinal outer-segment membranes
and their ability to span both leaﬂets of the lipid bilayer,
they are suggested to play a role in stabilizing cellular
membranes with high curvature, such as the rims of
photoreceptor disks (15). Fatty acid desaturase enzymes
are known to be inhibited in diabetes (22–24), and there is
emerging information suggesting that certain elongases
might also be affected (25). Thus, diabetes may result in
reduced fatty acid remodeling and, consequently, lead to
an accumulation of the substrates and depletion of the
products. The elongases Elovl2 and Elovl6 are ubiqui-
tously expressed in most tissues; however, retina ex-
presses Elovl2 at a very high level. Elovl2 is involved in
several steps of DHA22:6n3 biosynthesis (26). Retina has
a unique fatty acid proﬁle with one of the highest levels
of long-chain PUFAs, especially DHA22:6n3, in the body
(27). We have previously demonstrated that DHA22:6n3
has a pronounced anti-inﬂammatory effect on cytokine-
induced activation of the nuclear factor (NF)-B path-
way and adhesion molecule expression in human retinal
endothelial cells (HRECs) (28). Thus, perturbation of
lipid metabolism in diabetes with a subsequent decrease
in DHA22:6n3 could create proinﬂammatory conditions in
the retina, potentially contributing to the development
of diabetic retinopathy. The effect of diabetes on retinal
fatty acid elongases and desaturases and diabetes-in-
duced changes in retinal fatty acid remodeling has not
been analyzed and represents one of the goals of this
study.
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FIG. 1. De novo lipogenesis and PUFA remodeling pathways. Fatty acids are synthesized from glucose through de novo lipogeneses or converted
from dietary palmitic16:0, oleic18:1n9, linoleic18:2n6, and -linolenic18:3n3 acids to long-chain unsaturated fatty acids in vivo by a series of
desaturation (5-desaturase [5D], 6-desaturase [6D], or 9-desaturase [9D]) and elongation (Elovl1–7) reactions. Fatty acids that
accumulate in animal and human tissues are in solid boxes. Dietary linoleic18:2n6 and -linolenic18:3n3 acids are obtained from plants, and EPA20:5n3
and DHA22:6n3 are rich in ﬁsh oil. A recent study demonstrated that Elovl4 is necessary for synthesis of C26 and C28 VLCPUFAs from 24:5n3 and
24:6n3 fatty acid precursors and suggests that Elovl4 is also required for synthesis of >C28 VLCPUFAs. There is no interconversion between n3,
n6, and n9 fatty acids in animals.
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Reagents. High-performance liquid chromatography (HPLC)-grade acetoni-
trile, acetic acid, methanol, chloroform, streptozotocin (STZ), and commonly
used chemicals and reagents were from Sigma-Aldrich Chemical (St. Louis,
MO).
Animals and induction of STZ-induced diabetes. Male Sprague-Dawley
rats weighing 237–283 g were made diabetic with a single intraperitoneal
injection of 65 mg STZ per kg body wt. Body weight gains and blood glucose
for the control and STZ-induced diabetic groups were monitored biweekly. At
3–6 weeks after STZ injection, the animals were killed and blood plasma, liver,
and retina were recovered for analyses of fatty acid proﬁles and/or fatty acid
elongase and desaturase expression levels. To isolate the retina, the optic
nerve was cut out; the eye was opened; the coronary, cornea, and lens were
discarded; and the retina was separated from choroid, washed in PBS, and
frozen. Rats were maintained on Harlan-Teklad laboratory diet (no. 8,640) and
water ad libitum. The fatty acid composition of the diet was analyzed by
reverse-phase HPLC (RP-HPLC, see below) and found to be 16:0, 20.0%; 18:0,
1.8%; 18:1n9, 21.9%; 18:2n6, 50.8%; 18:3n3, 5.6%; 18:3n6, 0.1%; 20:4n6, 0.1%;
20:5n3, 0.4%; 22:5n3, 0.1%; and 22:6n3, 0.3%. Animal protocol was approved by
the Michigan State University Institutional Animal Care and Use Committee.
All experiments followed the guidelines set forth by the Association for
Research in Vision and Ophthalmology Resolution on Treatment of Animals in
Research.
RNA and protein isolation. Rat tissues were homogenized in Trizol reagent
(Invitrogen), and RNA was isolated according to manufacturer instructions.
After adding chloroform, the upper aqueous phase was separated and RNA
was precipitated with isopropyl alcohol, washed with 75% ethanol, and
redissolved in RNase-free water. Proteins from the same samples were
isolated by washing in Tris buffer (30 mmol/l Tris-HCl, pH 6.8, with 0.1% SDS)
followed by concentration on Amicon-15 (Millipore) centrifugal ﬁlters. After
concentration, protease/phosphatase inhibitor cocktail was added and sam-
ples were frozen until further analysis.
Real-time qRT-PCR. Transcript-speciﬁc primers were designed using
Primer3 software (available at http://frodo.wi.mit.edu/primer3/). First-strand
cDNA was synthesized using the SuperScript II RNase H Reverse
Transcriptase (Invitrogen, Carlsband, CA), and PCRs were performed in
triplicate as previously described (25). Transcripts of interest were
normalized to the abundance of cyclophilin mRNA. Rat gene–speciﬁc primers
used in this study were Elovl4: GAAGTGGATGAAAGACCGAGA (sense) and
GCGTTGTATGATCCCATGAA (antisense); Elovl7: TGGCGTTCAGCGATCT
TAC and GATGATGGTTTGTGGCAGAG; IL-6: CCAGGAAATTTGCCTATTGA
and GCTCTGAATGACTCTGGCTTT; VEGF A: GCTCTCTTGGGTGCACTGG
and CACCACTTCATGGGCTTTCT; and ICAM-1: CCACCATCACTGTGTAT
TCGTT and ACGGAGCAGCACTACTGAGA. All other primers for rat
elongases and desaturases were described previously (25).
Western blotting. Protein concentration was determined by a Qubit ﬂuorom-
eter (Invitrogen), according to manufacturer’s instructions, and equivalent
amounts of protein were loaded on the SDS-polyacrylamide (10%) minigels for
SDS-PAGE separation. The separated proteins were electrophoretically trans-
ferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA), blocked for 30
min at room temperature, and probed with primary rabbit anti-Elovl4 (Abcam)
and mouse anti- tubulin (Sigma) antibody followed by ﬂuorescent secondary
antibody (Invitrogen). The blots were analyzed by the Licor Odyssey scanner
and quantitated using Licor Odyssey software.
Total lipid extraction. Total lipids from retina, blood plasma, and liver were
extracted with chloroform-methanol (2:1, vol/vol), normalized to tissue
weight, dried, and resuspended as previously described (29). Acidiﬁcation of
total lipid extracts was omitted, as low pH has been demonstrated to destroy
acid-labile plasmalogen lipids (30), which are abundant in neural tissues. No
signiﬁcant decrease of recovery of abundant lipid classes was observed in the
absence of pH modiﬁcation (29). Blood plasma lipids were normalized to
protein, as measured by Qubit assay. Erythrocyte total lipids were extracted
from 100 mg of packed cells by a modiﬁed Rose and Oklander method (31).
Brieﬂy, lysed cells were combined with 6.8 ml of 80% 2-propanol, vortexed,
and incubated for1ho ni c ewith occasional mixing. Lipids were extracted
twice by addition of 3.2 ml of 100% chloroform and 1-h incubation on ice, with
phase separation after each chloroform addition achieved by centrifugation at
2,000g for 30 min. Acidiﬁcation of the extraction mixture was omitted, as it
was found that low pH destroys acid-labile plasmalogen lipids (30), which are
abundant in neural tissues. No signiﬁcant decrease of recovery of abundant
lipid classes was observed in the absence of pH modiﬁcation (29). Pooled lipid
extracts were dried, resuspended, and stored as described above.
Lipid analysis by nano-electrospray ionization tandem mass spectrom-
etry. Lipid extracts were introduced to a triple-quadrupole mass spectrometer
(Thermo Scientiﬁc model TSQ Quantum Ultra, San Jose, CA) for nano-
electrospray ionization tandem mass spectrometry (nESI-MS/MS) analysis of
lipid species as previously described (29). Identiﬁcation of phospholipid
species by precursor ion and neutral loss scan mode MS/MS was performed
according to published methods (29,32). Assignment of phosphatidylcholine
(GPCho) acyl substituents was achieved by negative ion mode analysis of
corresponding GPCho [MCl]
 ions byproduct ion scan mode MS/MS, as well
as by precursor ion scanning for m/z corresponding to speciﬁc deprotonated
fatty acyl ions. Peak ﬁnding and correction for
13C isotope effects was
performed using the Lipid Mass Spectrum Analysis (LIMSA) software version
1.0 peak model ﬁt algorithm (33). Quantitative analysis of the relative changes
in GPCho lipid abundances between control and diabetic samples was
achieved by normalization of the peak area of each detected GPCho m/z to
that of the GPCho(16:0/16:0) lipid present in each of the samples, after correction
for
13C isotope contributions.
Tissue fatty acid analysis by RP-HPLC. An aliquot of total lipids from
tissues and blood fractions was saponiﬁed (0.4 N KOH in 80% methanol, 50°C
for 1 h). Saponiﬁed fatty acids were acidiﬁed and extracted with diethyl ether
(according to Wang et al. [25]) and stored in methanol containing 1 mmol/l
butylated hydroxytoluene. Saponiﬁed free fatty acids were fractionated and
quantitated by RP-HPLC using a YMC J-Sphere (ODS-H80) column and a
sigmoidal gradient starting at 86.5% acetonitrile  acetic acid (0.1%) and
ending at 100% acetonitrile  acetic acid (0.1%) over 50 min with a ﬂow rate
of 1.0 ml/min using a Waters 600 controller. Fatty acids were introduced to the
HPLC by injection in methanol and detected using ultraviolet absorbance and
evaporative light scatter as previously described (25). Authentic fatty acid
standards (Nu-Chek Prep) were used to generate calibration curves for
veriﬁcation and quantiﬁcation of fatty acids.
Statistical analysis. Data are expressed as the means  SD. Student’s t test
was used for comparing data obtained from independent samples. Signiﬁ-
cance was established at P  0.05.
RESULTS
Body weight gain and blood glucose concentration of
experimental animals. As presented in Table 1, body
weight gain was signiﬁcantly slower in diabetic animals
compared with control animals. Blood glucose levels were
almost ﬁve times higher in diabetic animals compared with
controls. As this was a short-term diabetes study, A1C
levels were not measured.
Elongase and desaturase expression level in control
and diabetic animals. The gene expression levels of
elongases and desaturases in control retinas were deter-
mined by quantitative RT-PCR and compared with the
levels found in the livers of the same animals. Retinal-
speciﬁc elongase, Elovl4, had the highest expression level
among all the elongases in the retina and was not ex-
pressed in the liver. Retinas also had high levels of Elovl2
expression (Fig. 2A). Livers exhibited higher levels of
Elovl5 and 5-, 6-, and 9-desaturases than retina (Fig.
2A), and the liver proﬁle of all elongases and desaturases
agreed with our previous study (25).
In the liver, diabetes induced a 25% decrease in Elovl2
and a 33% decrease in Elovl6 expression, as well as an 85%
decrease in 9-desaturase (Fig. 2B) compared with con-
trols. In the retina, diabetes induced a 40% reduction in
Elovl4 and 50% reduction in Elovl2 expression levels (Fig.
2C). There was no signiﬁcant effect of diabetes on the
retinal desaturases (Fig. 2C). A decrease in Elovl4 protein
level was conﬁrmed by Western blot, as shown in Fig. 2D.
TABLE 1
Body weight gain and blood glucose concentrations of experi-
mental animals
n
Weight gain
(g/day)
Blood glucose
(mmol/l)
Control animals 4 4.05  0.65 4.33  0.29
Diabetic animals 7 2.32  0.89 20.80  1.16
Data are means  SD.
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betic animals. The control and diabetic blood plasma
fatty acid proﬁles 3 weeks after STZ injection are pre-
sented in Table 2. There was a tendency toward higher
total fatty acids level in diabetic versus control blood
plasma. We observed changes in the plasma fatty acid
proﬁle consistent with inhibition of fatty acid remodeling
in diabetes that leads to a lower end product–to–precursor
fatty acid ratio. There was a decrease in two major end
products of the PUFA synthesis pathway, arachidonic20:4n6
acid and DHA22:6n3, relative to their precursors, linoleic18:2n6
and -linolenic18:3n3 acid, respectively (Table 2). As a result
of these changes, we observed a decrease in unsaturation
index (the number of double bonds per fatty acyl residue)
and a decrease in long-chain–to–short-chain PUFA ratio in
diabetic versus control animals (Table 2).
Liver fatty acid proﬁles of control and diabetic
animals. The control and diabetic liver fatty acid proﬁles
3 weeks after STZ injection are presented in Table 3. There
was an increase in the linoleic acid18:2n6 level in the livers
of diabetic versus control animals that led to a decrease in
long-chain–to–short-chain PUFA ratio (Table 3). There
were no other signiﬁcant changes in liver fatty acid
proﬁles in diabetic versus control animals. The liver un-
saturation index and PUFA synthesis pathway end pro-
duct–to–precursor ratios did not change in diabetic versus
control animals (Table 3).
Retinal fatty acid proﬁles of control and diabetic
animals. Retina has a unique fatty acid proﬁle, with the
highest content of long-chain PUFAs in the body. In
agreement with other studies, retinal proﬁles were very
rich in DHA22:6n3 and arachidonic20:4n6 acid (Table 4). The
levels of linoleic18:2n6 and -linolenic18:3n3 acid in the retina
were very low; thus we did not calculate the PUFA
synthesis pathway end product–to–precursor ratios. Im-
portantly, the retinas of diabetic animals had 28% less
DHA22:6n3 compared with controls. As a result, we ob-
served a decrease in unsaturation index, a decrease in
long-chain–to–short-chain PUFA ratio, and a decrease in
the n3-to-n6 PUFA ratio in the retinas of diabetic versus
control animals (Table 4). Representative RP-HPLC chro-
matograms of saponiﬁed fatty acids from control and
diabetic retina are presented in Fig. 3A.
Retinal and erythrocyte phospholipid proﬁles of con-
trol and diabetic animals. In agreement with saponiﬁed
fatty acid proﬁle data, nESI-MS/MS analysis of the retina
lipid extracts of diabetic animals (n  3) showed a
signiﬁcant (up to 34%) decrease in the abundance of
glycerophospholipids containing DHA22:6n3 compared with
the control animals (n  3). For example, compare the
abundance of the GPCho(18:0/22:6) and GPCho(22:6/22:6) lipids
in the ratiometric analysis shown in Fig. 3B. Similar
decreases in the abundances of DHA22:6n3 containing lipids
were also observed for glycerophosphoethanolamine and
glycerophosphoserine lipids (data not shown). In contrast,
an increase (37%) in the abundance of the linoleic18:2n6
acid–containing GPCho(16:0/18:2) lipid was observed for the
same samples as shown in Fig. 3B. In addition to known
fatty acids identiﬁed by HPLC analysis, nESI-MS/MS anal-
ysis revealed several VLCPUFAs, primarily 32:6n3 and
34:6n3, esteriﬁed to GPCho in the retina. Interestingly,
GPCho(32:6/22:6) was signiﬁcantly decreased (24%) in dia-
betic retinas compared with controls, and there was a
nonsigniﬁcant decrease (9%) of GPCho(34:6/22:6).
In erythrocyte lipid extracts, an increase in the abun-
dance of linoleic18:2n6 acid–containing lipids, namely
GPCho(16:0/18:2) and GPCho(18:0/18:2), was observed be-
tween the diabetic and control samples, consistent with
the changes in retina lipids, as shown in Fig. 3C. Erythro-
cytes had very low levels of DHA-containing phospholipid
species, and there was no effect of diabetes on these
species. There was no detectable GPCho(32:6/22:6) or
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FIG. 2. Expression levels of elongases and desaturases in retinas and
livers of control and diabetic animals. Total RNA was extracted from
retinas and livers of normal control (n  4) and STZ-induced diabetic
animals (n  5) after 3–6 weeks of diabetes and analyzed by real-time
PCR for elongases 1–7 (E1–7) and 5-, 6-, and 9-desaturase (D5D,
D6D, and D9D) expression level. A comparison of the expression levels
in retina () and liver (p) of normal control animals is presented in A.
Diabetes-induced changes in liver elongase and desaturase expression
levels are presented in B (, control; f, diabetes). Diabetes-induced
changes in retinal expression levels are presented in C (, control; f,
diabetes). A Western blot of diabetes-induced changes in retina Elovl4
protein level (lanes 1–4 control, lanes 5–8 diabetic), and quantiﬁca-
tion by ratiometric comparison to tubulin, are presented in D (,
control; f, diabetes). Data are presented as means  SD of ﬁve
independent experiments. *Statistical signiﬁcance at P < 0.05.
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plasma (data not shown).
Inﬂammatory marker expression in control and dia-
betic retinas. As n3 PUFAs are known to have anti-
inﬂammatory properties, we hypothesized that a decrease
in n3 PUFAs would be associated with a proinﬂammatory
state in diabetic retinas. As shown in Fig. 4, diabetic
retinas had increased expression levels of several inﬂam-
matory markers including adhesion molecules (ICAM-1),
cytokines (IL-6), and growth factors (VEGF).
DISCUSSION
The association of dyslipidemia with the development of
diabetic retinopathy has been underscored by the Diabetes
Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications cohort study (8). Despite
this evidence, the experimental data on diabetes-induced
changes in lipid proﬁle and lipid metabolism in the retina
are not available. This is the ﬁrst comprehensive study
to analyze retinal-speciﬁc fatty acid proﬁles and metabo-
lism and to compare them to liver and blood plasma in
control and diabetic animals.
In this study utilizing STZ-induced diabetic rats, we
found a decreased level of DHA22:6n3, the major retinal
long-chain PUFA, in diabetic retina. This ﬁnding conﬁrmed
earlier studies showing a decrease in relative percentage
of DHA22:6n3 in the diabetic retina (34,35). In addition to
DHA22:6n3, VLCPUFAs including 32:6n3 and 34:6n3 were
TABLE 2
Blood plasma fatty acid proﬁles of control (n  4) and diabetic (n  7) animals
Fatty acids
Blood plasma
P Control animals Diabetic animals Difference
Total (nmol/mg protein) 2,262.55  639.64 3,286.54  766.69 0.0972
Mole % of total fatty acids
16:0 (palmitic) 2.19  1.17 3.70  0.46 1 0.0362*
18:0 (stearic) 2.25  0.34 2.08  0.40 0.5639
18:1n9 (oleic) 12.65  1.03 13.43  1.74 0.5126
18:2n6 (linoleic) 54.12  2.31 57.44  2.62 0.1207
18:3n3 (-linolenic) 1.93  0.32 2.71  0.36 1 0.0214*
18:3n6 (	-linolenic) 0.31  0.13 0.51  0.37 0.4028
20:3n6 (dihomo-	-linolenic) 0.84  0.12 0.87  1.15 0.9631
20:3n9 (mead) 0.52  0.32 0.35  0.30 0.4636
20:4n6 (arachidonic) 21.29  2.70 15.90  1.95 2 0.0161*
20:5n3 (eicosapentaenoic) 0.53  0.08 0.51  0.03 0.7449
22:5n3 (docosapentaenoic) 0.84  0.22 0.54  0.04 2 0.0235*
22:6n3 (docosahexaenoic) 2.78  0.23 1.72  0.25 2 0.0010*
Fatty acid ratios
Unsaturation index 61.58  18.05 38.91  5.56 2 0.0342*
LCPUFAa/SCPUFAa† 0.48  0.06 0.33  0.05 2 0.0107*
20:4n6/18:2n6 0.40  0.07 0.28  0.04 2 0.0232*
22:6n3/18:3n3 1.46  0.17 0.64  0.13 2 0.0002*
Data are means  SD. *P  0.05. †Long-chain PUFAs/short-chain PUFAs.
TABLE 3
Liver fatty acid proﬁles of control (n  4) and diabetic (n  7) animals
Fatty acids
Liver
P Control animals Diabetic animals Difference
Total (nmol/mg protein) 1,762.82  480.50 1,357.85  241.19 0.1,542
Mole % of total fatty acids
16:0 (palmitic) 26.73  8.18 17.55  3.25 0.0518
18:0 (stearic) 11.25  3.74 12.64  3.55 0.9706
18:1n9 (oleic) 3.11  1.03 3.39  1.04 0.4785
18:2n6 (linoleic) 33.14  5.34 39.90  2.71 1 0.0161*
18:3n3 (-linolenic) 0.49  0.11 0.59  0.11 0.2101
18:3n6 (	-linolenic) 0.13  0.14 0.09  0.04 0.2173
20:3n6 (dihomo-	-linolenic) 0.34  0.04 0.43  0.15 0.3942
20:3n9 (mead) 0.62  0.24 0.51  0.14 0.9340
20:4n6 (arachidonic) 19.87  4.43 21.37  2.50 0.4581
20:5n3 (eicosapentaenoic) 0.15  0.03 0.15  0.05 0.7777
22:5n3 (docosapentaenoic) 0.57  0.15 0.44  0.07 0.2388
22:6n3 (docosahexaenoic) 3.60  0.92 2.94  0.35 0.2294
Fatty acid ratios
Unsaturation index 5.05  1.82 6.56  1.31 0.0911
LCPUFA/SCPUFA† 0.74  0.07 0.64  0.02 2 0.0123*
20:4n6/18:2n6 0.60  0.07 0.53  0.03 0.1211
22:6n3/18:3n3 7.74  2.96 5.11  1.05 0.0979
Data are means  SD. *P  0.05. †Long-chain PUFAs/short-chain PUFAs.
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not detected in lipid classes other than GPCho and were
only detected in retina. Three weeks of diabetes reduced
retinal levels of 32:6n3-GPCho compared with controls. As
a result of these changes, the diabetic retina had a lower
unsaturation index and lower long-chain–to–short-chain
PUFA ratio. Moreover, there was a shift toward n3 PUFA–
deﬁcient, n6 PUFA–rich, proﬁle in the diabetic retina.
In general, n6 PUFAs induce, while n3 PUFAs inhibit,
inﬂammation, and the relative amount of these PUFAs
plays an important role in the regulation of immunity (36).
Our previous studies indicated that treatment of a cell type
affected by diabetic retinopathy, HRECs, with n6 PUFA
leads to a lipoxygenase-dependent increase in ICAM-1/
vascular cell adhesion molecule-1 expression (37). Con-
versely, we have demonstrated that DHA22:6n3 inhibited
cytokine-induced activation of the NFB signaling path-
way and adhesion molecule expression in HRECs (28).
Thus, a decrease in the n3-to-n6 PUFA ratio in the diabetic
retina observed in this study would create proinﬂamma-
tory conditions potentially contributing to the develop-
ment of diabetic retinopathy. Indeed, previous studies
demonstrated an upregulation in a number of inﬂamma-
tory markers in the retina early in diabetes: VEGF (4,5),
ICAM-1 (6,7), TNF- (8), and IL-6 (9). ICAM-mediated
leukostasis was detected within 1 week of diabetes in rats
(38,39). VEGF was shown to increase ICAM expression in
retinas of nondiabetic mice (40), and vitreal VEGF levels
were found to be correlated with that of IL-6 and severity
of diabetic retinopathy in diabetic patients (41).
In this study, we chose a cytokine (IL-6), a growth factor
(VEGF), and an adhesion molecule (ICAM-1) as readout of
an inﬂammatory status in the retinas of diabetic animals
with decreased n3/n6 PUFAs. mRNA levels of all three
markers were elevated in diabetic retinas compared with
controls.
Importantly, diabetes induced the most pronounced
changes in the retinal fatty acid proﬁle, whereas liver fatty
acid proﬁle was only slightly affected, indicating that the
disruption of retinal fatty acid metabolism in diabetes
might not simply be a result of altered liver metabolism.
Moreover, VLCPUFA-containing phospholipids detected in
the retina were not present in the liver or erythrocyte total
lipids. The fatty acid proﬁle in a particular peripheral
tissue depends on two factors: 1) the proﬁle in circulation
due to the diet and liver metabolism and 2) the ability of a
local tissue to remodel fatty acids. Retina has a unique
fatty acid proﬁle characterized by one of the highest
levels of DHA22:6n3 in the body and by the presence of
VLCPUFAs (27,42). While the expression level of retinal
desaturases was relatively low compared with retinal
elongases, it has been reported that retina can synthesize
DHA22:6n3 from -linolenic18:3n3 acid and EPA20:5n3 (43).
Although retina may obtain additional DHA22:6n3 by uptake
from the circulation, changes in the retinal fatty acid
proﬁles of diabetic animals did not mirror changes ob-
served in liver and plasma fatty acid proﬁles. Thus, a
retina-speciﬁc decrease in DHA22:6n3 in diabetes is likely to
be due to changes in retinal fatty acid metabolism.
To determine the effect of diabetes on retinal fatty acid
metabolism, we analyzed the level of fatty acid elongase
and desaturase gene expression in control and diabetic
animals. Retinas had a very high expression level of the
retinal-speciﬁc elongase, Elovl4, as well as high expression
levels of long-chain PUFA elongase Elovl2. 5-, 6-, and
9-desaturase levels were low compared with the liver
expression levels. The high levels of Elovl4 and Elovl2 and
low levels of desaturases suggest that the retina is prefer-
entially involved in production of very-long-chain fatty
acids and exhibits a low level of de novo lipogenesis. The
retinal elongase expression proﬁle that we observed likely
explains the high level of long-chain PUFAs in the retina
compared with liver and blood plasma levels. Elovl2
elongates C20–22 fatty acids (44–46). Elovl4 was recently
shown to be involved in VLCPUFA synthesis with sub-
strate speciﬁcity for C26–36 fatty acids (15). The role of
VLCPUFAs is not known. Because of their speciﬁc pres-
ence in tissues with high membrane curvature and their
ability to span both leaﬂets of the lipid bilayer, VLCPUFAs
are suggested to play the role of an anchor stabilizing high
TABLE 4
Retinal fatty acid proﬁles of control (n  4) and diabetic (n  7) animals
Fatty acids
Retina
P Control animals Diabetic animals Difference
Total (nmol/mg protein) 488.96  17.64 460.32  27.82 0.43
n3 fatty acids 225.1  4.23 166.34  20.66 2 0.0495*
n6 fatty acids 38.67  4.71 40.59  3.9 0.7693
Mole % of total fatty acids
16:0 (palmitic) 15.51  0.8 18.32  1.67 0.2046
18:0 (stearic) 18.61  0.97 21.98  2. 0.2046
18:1n9 (oleic) 10.58  0.2 12.9  0.77 1 0.0441*
18:2n6 (linoleic) 0.44  0.06 0.88  0.05 1 0.0051*
18:3n3 (-linolenic) 0.24  0.06 0.17  0.02 0.3556
20:3n6 (dihomo-	-linolenic) 0.11  0.02 0.04  0.01 0.0819
20:3n9 (mead) 0.97  0.06 1.09  0.2 0.6103
20:4n6 (arachidonic) 7.33  0.75 7.9  0.64 0.6004
20:5n3 (eicosapentaenoic) 0.04  0.02 0.01  0.01 0.2910
22:5n3 (docosapentaenoic) 0.47  0.08 0.28  0.05 0.1129
22:6n3 (docosahexaenoic) 45.37  1.32 35.47  2.71 2 0.0305*
Fatty acid ratios
Unsaturation index 20.77  1.63 14.9  2.57 0.1259
LCPUFA/SCPUFA† 80.39  4.86 42.53  3.94 2 0.0038*
% n3 fatty acids of total 46.12  1.41 35.93  2.77 2 0.0306*
Data are means  SD. *P  0.05. †Long-chain PUFAs/short-chain PUFAs.
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are mainly present in the rod outer-segment membrane (15),
where they are suggested to play a role in stabilizing the rims
of photoreceptor disks. This speciﬁc localization might ex-
plain low abundance of VLCPUFAs in the total retinal
lipids extracted in this study. At the same time, speciﬁc
localization suggests that VLCPUFAs might play an impor-
tant role in photoreceptor function. This study provides
the ﬁrst direct evidence that a signiﬁcant decrease in
Elovl4 in diabetic retina is indeed associated with a
decrease in VLCPUFA (i.e., 32:6n3) synthesis. Despite
lower abundance, diabetes-induced decrease in 32:6n3
containing GPCho (24%) was similar to the decrease in
DHA22:6n3 containing GPChos (15–34%). Elovl4 protein
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FIG. 3. Fatty acid analysis by RP-HPLC and comparative MS/MS analysis of GPCho lipids in control (n  3) and diabetic (n  3) animals at 3–6
weeks post-STZ injection. A: Identiﬁcation and quantiﬁcation of diabetes-induced changes in total retina saponiﬁed fatty acids. Top: RP-HPLC
chromatogram of a mixture of authentic fatty acid standards. Middle: Control retina saponiﬁed fatty acids. Bottom: Diabetic retina saponiﬁed
fatty acids. B: Ratiometric analysis of changes in GPCho lipid abundance (Abund.) between control () and diabetic (f) retina. GPCho species
were detected by nESI-MS/MS using PI m/z 184 and further characterized as described in RESEARCH DESIGN AND METHODS. C: Ratiometric analysis of
changes in GPCho lipid abundance between control and diabetic erythrocytes. Data are presented as means  SD. *Statistical signiﬁcance at P <
0.05.
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degree (73%) compared with mRNA expression (40%),
suggesting control of Elovl4 expression at both transcrip-
tional and translational levels. Although decrease of
VLCPUFAs is most likely to arise from Elovl4 loss, another
plausible explanation could be that this reduction was due to
reduction in VLCPUFA precursor lipids, EPA20:5n3, and/or
DHA22:6n3. This possibility can be tested in the future by
determining whether downregulation of VLCPUFAs in
diabetes persists in animals supplemented with high-
EPA20:5n3/DHA22:6n3 diet.
Another possibility could be that high level of reactive
oxygen species in diabetic retina leads to degradation of a
highly oxidation-prone DHA molecule. Previous studies
using the same STZ-induced diabetic model of similar
duration, however, did not ﬁnd oxidized DHA products in
diabetic retina (47).
Several Elovl4 gene mutations have been recently iden-
tiﬁed in pathogenesis of another retinal disease, Stargardt-
like macular dystrophy (19–21). Stargardt-like macular
dystrophy is an autosomal-dominant disorder due to a
dominant-negative effect of the mutated Elovl4 on wild-
type protein (19). As Elovl4 is highly expressed in the
photoreceptors (19,21), it is not surprising that mutant
Elovl4 transgenic mice are characterized by lipofuscin
accumulation, abnormal electrophysiology, and photore-
ceptor degeneration (20). Although photoreceptors are not
the primary site of diabetic retinopathy, several abnormal-
ities in neural retina have been associated with the devel-
opment of diabetic retinopathy (48,49). The decrease in
Elovl4 observed in this study would not be expected to
have as dramatic an effect on photoreceptor viability as
the dominant-negative mutation in Elovl4. However, the
reduction in Elovl4 in diabetic retina could be responsible
for more subtle changes in photoreceptor/RPE cell func-
tion that could lead to metabolic changes in the whole
retina and eventually contribute to the pathology charac-
teristic of diabetic retinopathy.
In conclusion, a decrease in the expression level of
retinal fatty acid elongases Elovl2 and Elovl4 and concom-
itant decrease in the major n3 PUFA, DHA22:6n3, as well as
the VLCPUFA32:6n3, results in an increased n6-to-n3 PUFA
ratio in the diabetic retina that likely creates a proinﬂam-
matory state contributing to the development of diabetic
retinopathy. Increasing the gene expression of fatty acid
elongases in the retina represents a potential therapeutic
strategy for modulating fatty acid metabolism and altering
the pathogenesis of diabetic retinopathy.
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